Although MHC binding prediction algorithms can reduce the number of mutations to be considered as candidate NeoAg, they cannot inform on which mutations will be naturally processed and presented at the surface of a tumor cell expressing the source protein or cross-presented by professional APC (26). This evidence concerns the gene APC and neoplasm.